Molecular assessment of drug resistance in Plasmodium falciparum from Bahr El Gazal Province, Sudan

Aims  To assess resistance to chloroquine (CQ) and sulphadoxine/pyrimethamine (SP) in a Sudanese parasite population.

[1]  R. Price,et al.  Effects of artemisinin derivatives on malaria transmissibility , 1996, The Lancet.

[2]  P. Newton,et al.  A selective sweep driven by pyrimethamine treatment in southeast asian malaria parasites. , 2003, Molecular biology and evolution.

[3]  D. Hartl,et al.  Principles of population genetics , 1981 .

[4]  P. Newton,et al.  A selective sweep driven by pyrimethamine treatment in SE Asian malaria , 2003 .

[5]  O. Doumbo,et al.  Application of a molecular marker for surveillance of chloroquine-resistant falciparum malaria , 2001, The Lancet.

[6]  A. Muñoz,et al.  Determinants of treatment response to sulfadoxine-pyrimethamine and subsequent transmission potential in falciparum malaria. , 2002, American journal of epidemiology.

[7]  J. Wootton,et al.  Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. , 2000, Molecular cell.

[8]  D. Warhurst.  A molecular marker for chloroquine-resistant falciparum malaria. , 2001, The New England journal of medicine.

[9]  F. Nosten,et al.  Rapid genotyping of loci involved in antifolate drug resistance in Plasmodium falciparum by primer extension. , 2002, International journal for parasitology.

[10]  K. Bojang,et al.  Efficacy of artesunate plus pyrimethamine-sulphadoxine for uncomplicated malaria in Gambian children: a double-blind, randomised, controlled trial , 2000, The Lancet.

[11]  Jody Hey,et al.  Principles of population genetics (2nd edn) , 1989 .

[12]  H. Babiker,et al.  High-level chloroquine resistance in Sudanese isolates of Plasmodium falciparum is associated with mutations in the chloroquine resistance transporter gene pfcrt and the multidrug resistance Gene pfmdr1. , 2001, The Journal of infectious diseases.

[13]  T. Jelínek,et al.  Diagnostic value of molecular markers in chloroquine-resistant falciparum malaria in Southern Mauritania. , 2002, The American journal of tropical medicine and hygiene.

[14]  C. Drakeley,et al.  Artesunate reduces but does not prevent posttreatment transmission of Plasmodium falciparum to Anopheles gambiae. , 2001, The Journal of infectious diseases.

[15]  J. Kublin,et al.  Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. , 2002, The Journal of infectious diseases.

[16]  B. Sharp,et al.  Antifolate antimalarial resistance in southeast Africa: a population-based analysis , 2003, The Lancet.

[17]  I. Bygbjerg,et al.  Pyrimethamine/sulfadoxine combination in the treatment of uncomplicated falciparum malaria: relation between dihydropteroate synthase/dihydrofolate reductase genotypes, sulfadoxine plasma levels, and treatment outcome. , 2002, The American journal of tropical medicine and hygiene.

[18]  A. Nzila,et al.  Chloroquine, sulfadoxine-pyrimethamine and amodiaquine efficacy for the treatment of uncomplicated Plasmodium falciparum malaria in Upper Nile, south Sudan. , 2003, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[19]  O. Doumbo,et al.  P. falciparum dihydrofolate reductase and dihydropteroate synthase mutations: epidemiology and role in clinical resistance to antifolates. , 1998, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[20]  N. White,et al.  Delaying antimalarial drug resistance with combination chemotherapy. , 1999, Parassitologia.